Cytek Biosciences appoints Dr. Vera Imper to board of directors

Cytek Biosciences, Inc.

Board expanded from six to seven members; Dr. Imper appointed as Class II director effective Dec 31, 2021.
Dr. Imper receives $40,000 annual retainer and initial equity award of $300,000 (28,598 option shares at $16.32).
Initial options vest monthly over three years; annual equity grant of $160,000 at 2022 annual meeting.
Dr. Imper determined independent under Nasdaq rules; standard indemnification agreement in place.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Vera Imper

Class II director

CTKB · Cytek Biosciences, Inc.

Effective: 2021-12-31
Filed: January 6, 2022, 6:59 PM ET

the Board unanimously voted to (i) increase the number of authorized directors on the Board from six to seven and (ii) appoint Dr. Vera Imper to serve as a Class II director of the Company, effective December 31, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Vera Imper was appointed as Class II director at Cytek Biosciences, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

the Board unanimously voted to (i) increase the number of authorized directors on the Board from six to seven and (ii) appoint Dr. Vera Imper to serve as a Class II director of the Company, effective December 31, 2021

View on SEC.gov

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-003544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.